A phase I study of human lymphoblastoid interferon administered by continuous intravenous infusion

1982 ◽  
Vol 9 (2) ◽  
pp. 97-102 ◽  
Author(s):  
A. Z. S. Rohatiner ◽  
F. R. Balkwill ◽  
D. B. Griffin ◽  
J. S. Malpas ◽  
T. A. Lister
1988 ◽  
Vol 6 (1) ◽  
pp. 158-162 ◽  
Author(s):  
B Reichman ◽  
M Markman ◽  
T Hakes ◽  
N Kemeny ◽  
D Kelsen ◽  
...  

In an effort to maximize both local-regional and systemic drug exposure to tumor in the peritoneal cavity, a phase I study was conducted that examined the simultaneous daily intraperitoneal (IP) and continuous intravenous infusion (CVI) of fluorouracil (5-FU) to 32 patients with refractory cancer. IP 5-FU administered at 1,000 mg/d with concurrent 5-FU by CVI at 1,000 mg/m2/d for four consecutive days was well tolerated. One patient with a primary gastrointestinal (GI) malignancy with minimal volume disease experienced a surgically defined complete remission. In theory, this regimen may demonstrate clinical utility as an adjuvant treatment of certain GI malignancies. Future studies are planned in this clinical setting.


1994 ◽  
Vol 86 (5) ◽  
pp. 368-372 ◽  
Author(s):  
G. F. Fleming ◽  
M. J. Ratain ◽  
S. M. O'Brien ◽  
R. L. Schilsky ◽  
P. C. Hoffman ◽  
...  

2000 ◽  
Vol 11 (3) ◽  
pp. 333-338 ◽  
Author(s):  
A.W. Tolcher ◽  
C. Aylesworth ◽  
J. Rizzo ◽  
E. Izbicka ◽  
E. Campbell ◽  
...  

2018 ◽  
Vol 29 ◽  
pp. viii139-viii140 ◽  
Author(s):  
K.L. Moek ◽  
W.M. Fiedler ◽  
J.C. von Einem ◽  
H.M. Verheul ◽  
T. Seufferlein ◽  
...  

1992 ◽  
Vol 30 (3) ◽  
pp. 226-228 ◽  
Author(s):  
D. Khayat ◽  
C. Borel ◽  
M. Azab ◽  
D. Paraisot ◽  
E. Malaurie ◽  
...  

1989 ◽  
Vol 24 (4) ◽  
Author(s):  
JamesF. Bishop ◽  
Derek Raghavan ◽  
IanN. Olver ◽  
Phillip Reece ◽  
Raymond Morris ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document